Madrigal Pharmaceuticals, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:MDGL) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Market Capitalization 9.6916 B
Employee 528
Founded 2011
CEO Paul A. Friedman
Website www.madrigalpharma.com
Headquarter Delaware, United States
FIGI BBG000QS6NV8
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

9.69 B Market capitalization

Price to earnings ratio

-45.32

Price to sales ratio

13.63

Dividends per share

—

Dividend yield %

—

Nachrichten

Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL)

Novo Nordisk Stock: Why Wegovy Growth Beats Wall Street Expectations (NYSE:NVO)

H.C. Wainwright bekräftigt Kaufempfehlung für Madrigal – Aktie trotz Kursrückgang unterbewertet

H.C. Wainwright reiterates Madrigal Pharmaceuticals stock rating at buy

Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down

Lam Research, Goldman Sachs among market cap stock movers on Thursday

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript

Oracle, Deere among market cap stock movers on Thursday

Madrigal: Starker Rezdiffra-Umsatz kann deutliche Gewinnverfehlung nicht ausgleichen

Madrigal Q4 2025 slides: Rezdiffra nears $1B in first year sales despite EPS miss

Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates

Madrigal Pharma: Quartalsverlust überschattet Umsatzplus – Aktie fällt um über 5 %